DDRugging glioblastoma: understanding and targeting the DNA damage response to improve future therapies.

ABSTRACT: Glioblastoma is the most frequently diagnosed type of primary brain tumour in adults. These aggressive tumours are characterised by inherent treatment resistance and disease progression, contributing to ~ 190 000 brain tumour-related deaths globally each year. Current therapeutic interventions consist of surgical resection followed by radiotherapy and temozolomide chemotherapy, but average survival is typically around 1 year, with < 10% of patients surviving more than 5 years. Recently, a fourth treatment modality of intermediate-frequency low-intensity electric fields [called tumour-treating fields (TTFields)] was clinically approved for glioblastoma in some countries after it was found to increase median overall survival rates by ~ 5 months in a phase III randomised clinical trial. Howev

SUBMITTER: Rominiyi O 

PROVIDER: S-EPMC8732357 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature